Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND: Dexamethasone for Sepsis-associated ARDS
NCT07576660Phase 3Recruiting
- Sponsor
- Southeast University
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Dexamethasone Group with Placebo Group (2 arms). Primary endpoint: 90-day all-cause mortality. Started Aug 2026; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07576660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576660.